Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sinovant to Start China Trials of Derazantinib for Bile Duct Cancer

publication date: Apr 29, 2019

Shanghai's Sinovant Sciences was given the go-ahead to begin a China registrational trials of derazantinib as a second-line treatment for intrahepatic cholangiocarcinoma (bile duct cancer). Derazantinib is an oral pan-FGFR (fibroblast growth factor receptor) inhibitor being developed to treat iCCA and other tumors with high FGFR mutation rates. Roivant, Sinovant's parent, in-licensed China rights to derazantinib from ArQule in 2018, and then included it in a package of 11 drugs sent to Sinovant for China development. More details....

Stock Symbol: (NSDQ: ARQL)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.